Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective

Authors

  • Burak Arslan Department of Medical Biochemistry, Gazi University Faculty of Medicine, Ankara, Turkey; Department of Medical Biochemistry, Erciş State Hospital, Van, Turkey https://orcid.org/0000-0001-7229-3226
  • Gökçe Ayhan Arslan Department of Neurology, Erciş State Hospital, Van, Turkey https://orcid.org/0000-0002-1099-3443
  • Aslı Tuncer Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Rana Karabudak Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Aylin Sepici Dinçel Department of Medical Biochemistry, Gazi University Faculty of Medicine, Ankara, Turkey https://orcid.org/0000-0001-5847-0556

DOI:

https://doi.org/10.17305/bjbms.2021.7326

Keywords:

Multiple sclerosis, neurofilament light chain, SIMOA, ELISA

Abstract

The neurofilament light chain (NfL) is a promising biomarker in the diagnosis, prognosis, and treatment response evaluation of neurological diseases. The aims of this study were to compare the cerebrospinal fluid (CSF) NfL levels in multiple sclerosis (MS) and certain non-demyelinating diseases of the central nervous system (NDCNS); to determine the relationship between clinical and radiological features and CSF NfL levels in patients with MS; and to compare the enzyme-linked immunosorbent assay (ELISA) and single molecule array (SIMOA) methods for NfL measurement using paired CSF and serum samples. We retrospectively analyzed the clinical data and performed NfL measurements in CSF and serum samples of newly diagnosed and treatment-naive patients with CNS diseases evaluated between 1 January 2019 and 1 January 2020. Eligible patients were divided into three groups: MS (n=23), differential diagnosis of MS (n=19), and NDCNS (n=42). First, we compared the CSF NfL levels among the three groups using the previously validated CSF ELISA assay. Next, we evaluated the relationship between CSF NfL levels and the clinical and radiological findings in MS group. Finally, we compared CSF and serum samples from patients of the MS groups (paired serum and CSF samples, n=19) using two different methods (ELISA and SIMOA). The CSF NfL level was the highest in the NDCNS group (1169.64 [535.92-5120.11] pg/mL, p=0.025). There was a strong positive correlation between the number of T2 lesions and CSF NfL level (r=0.786, p<0.001) in the MS group. There was excellent consistency between ELISA and SIMOA for CSF samples, but not for serum samples. Our results indicated that CSF NfL levels may also be used in the management of NDCNS and that SIMOA is the most reliable method for serum NfL determination.

Downloads

Download data is not yet available.
Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective

Downloads

Published

2022-04-30 — Updated on 2022-09-16

How to Cite

1.
Arslan B, Ayhan Arslan G, Tuncer A, Karabudak R, Sepici Dinçel A. Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective. Bosn J of Basic Med Sci [Internet]. 2022Sep.16 [cited 2022Sep.25];22(5):699-706. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/7326

Issue

Section

Biochemistry